Loading financial data...

Adaptive Biotechnologies Corp (ADPT) Financial Statements | Global Financial Data

Adaptive Biotechnologies Corp

ADPTSEC EDGAR

Biological Products, (No Diagnostic Substances)(WA)CIK: 1478320

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$170.3M	$185.3M	$154.3M	$98.4M	$85.1M
Cost of Goods and Services Sold	$75.6M	$57.9M	$49.3M	$22.5M	$22.3M
Research and Development Expense	$122.1M	$141.8M	$142.3M	$116.1M	$70.7M
Operating Income (Loss)	-$227.0M	-$200.2M	-$209.0M	-$152.8M	-$78.4M
Interest Expense	$13.8M	$4.2M	$4.2M	$4.2M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$225.3M	-$200.4M	-$207.3M	-$146.2M	-$68.6M
Income Tax Expense (Benefit)	$0.00	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$539.4M	$661.1M	$856.6M	$923.3M	$1.1B
Assets, Current	$283.8M	$410.2M	$562.1M	$402.7M	$726.9M
Cash and Cash Equivalents, at Carrying Value	$47.9M	$65.1M	$90.0M	$139.1M	$123.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$41.7M	$38.0M	$40.1M	$17.4M	$10.0M
Inventory, Net	$8.4M	$14.4M	$14.5M	$19.3M	$14.1M
Liabilities	$336.9M	$352.9M	$392.5M	$319.2M	$373.1M
Liabilities, Current	$98.1M	$88.0M	$109.8M	$113.8M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$156.3M	-$183.9M	-$192.7M	-$149.7M	$205.4M
Net Cash Provided by (Used in) Investing Activities	$129.6M	$2.9M	$181.2M	-$117.0M	-$481.7M
Net Cash Provided by (Used in) Financing Activities	$2.2M	$132.3M	$27.1M	$293.6M	$319.9M
Payments to Acquire Property, Plant, and Equipment	$10.7M	$16.3M	$61.7M	$18.8M	$11.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)